Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.
The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a treatment for Ewing's Sarcoma, with a goal of preclinical evaluation leading to clinical testing.
Researchers at the National Cancer Institute (NCI) developed orthotopic allograft models for pancreatic cancer that utilize cells or tumor fragments implanted into the cancer-free pancreata of recipient immunocompetent mice. NCI seeks licensees to commercialize this invention.
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.
The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.
GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). NICHD seeks parties to license this invention towards commercialization.
Researchers at the National Cancer Institute (NCI) have developed an improved class of heptamethine cyanine fluorophore dyes useful for imaging applications in the near-IR range (750-850 nm). A new chemical reaction has been developed that provides easy access to novel molecules with improved properties. Specifically, the dyes display greater resistance to thiol nucleophiles, and are more robust while maintaining excellent optical properties. The dyes have been successfully employed in various in vivo imaging applications and in vitro labeling and microscopy applications. The NCI seek co-development or licensees to develop them as targetable agents for optical-guided surgical interventions.
Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of cnidarins.
A considerable effort has been devoted to identifying and targeting specific extracellular cancer markers using antibody based therapies. However, diminished access to new cancer cell surface markers has limited the development of corresponding antibodies. NCI Technology Transfer Center is seeking to license cancer immunotherapy using virus-like particles.
The National Cancer Institute is seeking parties interested in collaborative research to co-develop, evaluate, or commercialize a new mouse model for monoclonal antibodies and immunoconjugates that target malignant mesotheliomas. Applications of the technology include models for screening compounds as potential therapeutics for mesothelioma and for studying the pathology of mesothelioma.
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target B-cell maturation antigen (BCMA) are strong therapeutic candidates for patients with plasma cell malignancy diseases such as, multiple myeloma (MM), as well as for patients with Hodgkin’s lymphoma. BCMA is a cell surface protein preferentially expressed on a subset of B cells and mature plasma cells, but not on other cells in the body. The limited expression of BCMA on B and plasma cells makes BCMA an attractive therapeutic target for B cell and plasma cell malignancy diseases. The 12 anti-BCMA CARs described are fully human CARS and have the potential to treat patients with various plasma cell and B cell malignancy diseases.
Researchers at the National Cancer Institute (NCI) developed novel groups of cyanine (Cy) based antibody-drug conjugate (ADC) chemical linkers that undergo photolytic cleavage upon irradiation with near-IR light. By using the fluorescent properties of the Cy linker to monitor localization of the ADC, and subsequent near-IR irradiation of cancerous tissue, drug release could be confined to the tumor microenvironment.
Researchers at the National Cancer Institute developed a novel method of immunogenic modulation in androgen and endocrine deprivation therapy. A combination of hormone therapy with immunotherapies such as PROSTVAC™, a Brachyury vaccine, PROVENGE™, ipilumimab, nivolumab, XOFIGO™, PANVAC, a yeast-MUC-1 immunotherapeutic, or HERCEPTIN™ can benefit prostate and breast cancer patients, especially those who have acquired resistances. The researchers seek parties to co-develop this method.
NCI researchers developed a combination therapy of histone deacetylase (HDAC) inhibitors and immunotherapies, such as checkpoint inhibitors, virus-based vaccines, monoclonal antibodies, cell-based treatments or radiopharmaceuticals. The NCI Laboratory of Tumor Immunology and Biology seeks parties to license or co-develop this method.
Investigators at the National Cancer Institute discovered a set of biomarkers that can identify patients with early stage lung cancer who are at a high risk of relapse. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy. The NCI seeks parties to license or co-develop the invention.
NCI seeks partners to commercialize Griffithsin and Griffithsin tandemers as therapeutics for HIV infections that are resistant to native GRFT, specifically, additional studies on stability, toxicity, immunogenicity, and large-scale production.
Researchers at the NICHD developed a method for non-invasively determining the distribution of pore lengths and radii within a matrix thereby characterizing cognitive defects observed in patients with Traumatic Brain Injury (TBI). The NICHD seeks licensing and/or co-development research collaborations to bring this invention to the public.
The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.
Researchers at the National Cancer Institute (NCI) have developed a technology that provides methods of performing adoptive cell transfer (ACT), an immunotherapeutic approach for cancer treatment, by administering a heterodimeric Interleukin 15/Interleukin 15 receptor alpha (IL-15/IL-15Rα) complex (hetlL-15) in the absence of lymphodepletion, thereby eliminating any lymphodepletion-associated detrimental side effects.